CD8+ T-Cell Signatures as Prognostic and Immunotherapy Response Predictors in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Immunology
• Genomics

Background:

• Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers, with low survival rates.
• Current immunotherapies benefit only a subset of NSCLC patients, necessitating predictive biomarkers.
• CD8+ T cells are vital for anti-cancer immunity and immunotherapy response.

Purpose of the Study:

• To identify and validate a novel biomarker signature for predicting prognosis and immunotherapy response in NSCLC.
• To investigate the role of CD8+ T cells in NSCLC patient outcomes.
• To develop a robust biomarker for personalized NSCLC treatment strategies.

Main Methods:

• Utilized single-cell RNA sequencing (scRNA-seq) on four NSCLC samples.
• Analyzed 1,000 NSCLC samples from The Cancer Genome Atlas (TCGA).
• Included 196 NSCLC samples from the GSE37745 cohort for validation.

Main Results:

• A novel biomarker signature based on CD8+ T-cell marker genes was identified.
• Favorable risk profiles in NSCLC patients correlated with specific immune cell patterns.
• CD8+ T cells were confirmed as crucial predictors of NSCLC prognosis and treatment efficacy.

Conclusions:

• The developed biomarker signature effectively predicts therapeutic responses in NSCLC.
• CD8+ T cells play a pivotal role in NSCLC progression and response to immunotherapy.
• This signature can guide personalized treatment decisions for NSCLC patients, improving outcomes.